Track Cell Source's total liabilities ($19M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Cell Source (CLCS) currently reports a total liabilities of $19M as of December 2024. That compares with $16M in the prior-year period — up 20.7% year over year. Use the charts on this page to explore Cell Source's total liabilities history and peer comparisons.
Cell Source's total liabilities increased from $16M to $19M — a 20.7% year-over-year increase (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Cell Source reported $19M in total liabilities as of December 2024. That compares with $16M in the prior-year period — up 20.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total liabilities of $19M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cell Source, and consider following CLCS for alerts when major investors trade the stock.
Cell Source is classified in the Healthcare sector. On total liabilities, it currently shows $19M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CLCS with unrelated industries.